SPAC Social Capital Suvretta III closes $250M IPO and funds trust account

PROKIDNEY CORP.

IPO of 25M Class A shares at $10.00 closed July 2, 2021; gross proceeds $250M.
Concurrent private sale of 640k Private Placement Shares to sponsor for $6.4M.
Proceeds placed in trust at JP Morgan/Continental; restricted until business combination or 24-month deadline.
Marc Semigran appointed to board as chairman of audit, compensation, and nominating committees.
Company targets biotechnology industry, specifically the organ space subsector.

item 1.01 item 3.02 item 5.02 item 5.03 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Marc Semigran

Director

PROK · PROKIDNEY CORP.

Effective: 2021-06-29
Filed: July 2, 2021, 7:59 PM ET

On June 29, 2021, in connection with the IPO, Marc Semigran was appointed to the board of directors of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Marc Semigran was appointed as Director at PROKIDNEY CORP..

Action: appointed
Role: Director

Exact text from the filing

On June 29, 2021, in connection with the IPO, Marc Semigran was appointed to the board of directors of the Company

View on SEC.gov

PROKIDNEY CORP. filing history →

Source: SEC EDGAR

accession 0001193125-21-207646

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.